Vertex Pharmaceuticals Inc

詳細情報 Vertex Pharmaceuticals Inc 企業名

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.

企業情報

企業コードVRTX

会社名Vertex Pharmaceuticals Inc

上場日Jul 24, 1991

最高経営責任者「CEO」Dr. Reshma Kewalramani

従業員数6100

証券種類Ordinary Share

決算期末Jul 24

本社所在地50 Northern Avenue

都市BOSTON

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02210

電話番号16173416393

ウェブサイトhttps://www.vrtx.com/

企業コードVRTX

上場日Jul 24, 1991

最高経営責任者「CEO」Dr. Reshma Kewalramani

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

16.13K

--

Mr. Lloyd A. Carney

Independent Director

7.12K

+12.60%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.83K

+8.93%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+86.33%

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

51.81K

+23.92%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+12.50%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

32.67K

+40.46%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

30.30K

+19.95%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

24.47K

--

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

17.61K

+5.74%

収益内訳

通貨: USD更新時刻: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

事業別USD

会社名

収益

比率

TRIKAFTA

2.54B

91.86%

Other product revenues

156.60M

5.67%

ALYFTREK

53.90M

1.95%

CASGEVY

14.20M

0.51%

地域別USD

会社名

収益

比率

United States

1.65B

59.91%

Europe

826.60M

29.95%

Other

280.10M

10.15%

事業別

地域別

事業別USD

会社名

収益

比率

TRIKAFTA

2.54B

91.86%

Other product revenues

156.60M

5.67%

ALYFTREK

53.90M

1.95%

CASGEVY

14.20M

0.51%

株主

更新時刻: Thu, May 15

株主統計

種類

株主統計

比率

Capital World Investors

11.13%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

5.67%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Global Advisors (US)

4.60%

Other

63.78%

株主統計

比率

Capital World Investors

11.13%

The Vanguard Group, Inc.

9.31%

Capital Research Global Investors

5.67%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Global Advisors (US)

4.60%

Other

63.78%

種類

株主統計

比率

Investment Advisor

59.89%

Investment Advisor/Hedge Fund

28.41%

Research Firm

2.57%

Pension Fund

2.45%

Bank and Trust

2.05%

Sovereign Wealth Fund

1.44%

Hedge Fund

1.30%

Insurance Company

0.16%

Individual Investor

0.14%

Other

1.60%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

2023Q2

2488

248.89M

96.55%

-7.11M

2023Q1

2468

250.11M

97.13%

-4.74M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Capital World Investors

28.53M

11.11%

+207.61K

+0.73%

Mar 31, 2025

The Vanguard Group, Inc.

23.38M

9.1%

+232.41K

+1.00%

Mar 31, 2025

Capital Research Global Investors

14.54M

5.66%

+4.11M

+39.38%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

14.00M

5.45%

-330.35K

-2.31%

Mar 31, 2025

State Street Global Advisors (US)

11.79M

4.59%

-190.75K

-1.59%

Mar 31, 2025

Fidelity Management & Research Company LLC

7.62M

2.97%

-1.49M

-16.32%

Mar 31, 2025

Jennison Associates LLC

5.06M

1.97%

+744.68K

+17.25%

Mar 31, 2025

Geode Capital Management, L.L.C.

5.76M

2.24%

+113.52K

+2.01%

Mar 31, 2025

Wellington Management Company, LLP

5.45M

2.12%

-461.34K

-7.80%

Mar 31, 2025

Invesco Capital Management (QQQ Trust)

5.31M

2.07%

-20.76K

-0.39%

Jun 30, 2025

詳細を見る

387.770USD

Vertex Pharmaceuticals Inc

387.770

概要

企業名

金融